文献速递造血干细胞移植与细胞治疗

单剂CD137抗体药物偶联物可保护恒河猴异基因造血干细胞移植受者免于急性移植物抗宿主病

A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD.
PubMed 文献 · Blood · 2025-01-01

研究开发了单剂抗CD137抗体药物偶联物(CD137-ADC)方案,在移植当天给药、不加额外免疫抑制。该方案可清除人和非人灵长类活化T细胞,在小鼠异种aGVHD模型及MHC单倍相合HCT恒河猴中有效预防aGVHD,但受者恒河猴淋巴隐病毒再激活风险较高,可用利妥昔单抗控制。

要点

  • 单剂CD137-ADC在移植当天给药、不加额外免疫抑制,可特异性清除活化PD-1+ CD4和CD8 T细胞。
  • CD137-ADC处理组恒河猴造血和免疫重建良好,T细胞恢复特征与长期无aGVHD生存相关。
  • CD137-ADC处理组恒河猴淋巴隐病毒再激活风险较高,与滤泡辅助T细胞等重建相关,可用利妥昔单抗控制。

核心结论

  • 单剂CD137-ADC可有效清除同种反应性T细胞并预防aGVHD,作者认为应谨慎探索临床转化。

研究设计与样本

  • 研究为临床前研究,包含体外实验、小鼠异种aGVHD模型(接受人外周血单个核细胞)及MHC单倍相合HCT恒河猴模型。
  • CD137-ADC为单剂、移植当天给药、不加额外免疫抑制的aGVHD预防方案。

主要发现

  • CD137-ADC可清除人和非人灵长类活化T细胞,并在小鼠异种aGVHD模型和MHC单倍相合HCT恒河猴中高效预防aGVHD。
  • 流式细胞术分析显示,HCT后第一周内CD137-ADC特异性清除活化PD-1+ CD4和CD8 T细胞,同时保留初始和PD-1-OX40+记忆T细胞亚群。
  • CD137-ADC处理组恒河猴造血和免疫重建良好,T细胞恢复特征(表达TRAIL的CD4记忆T细胞、表达CX3CR1的终末分化CD8 T细胞及CD4 FoxP3+调节性T细胞重建)与长期无aGVHD生存相关。
  • CD137-ADC处理组恒河猴淋巴隐病毒再激活风险较高,与滤泡辅助T细胞、干扰素信号相关记忆及γδT细胞亚群重建相关,该再激活可用利妥昔单抗控制。

临床怎么用

  • 作者认为单剂CD137-ADC清除同种反应性T细胞并预防aGVHD的结果提示应谨慎探索临床转化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid CD137 upregulation on alloreactive T cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody-drug conjugate (CD137-ADC) administered on the day of transplant without additional immunosuppression. The CD137-ADC depleted both human and nonhuman primate (NHP) activated T cells and proved highly effective in preventing xenogeneic aGVHD in mice receiving human peripheral blood mononuclear cells, as well as in NHP undergoing major histocompatibility complex (MHC)-haploidentical HCT. Flow cytometry analysis of NHP T cells indicated specific depletion of activated PD-1+ CD4 and CD8 T cells, while sparing naïve and PD-1-OX40+ memory T-cell subsets during the first week after HCT. CD137-ADC-treated NHP recipients demonstrated robust hematopoietic and immune reconstitution. Hallmarks of T-cell recovery after CD137-ADC, which were associated with long-term aGVHD-free survival, included reconstitution of CD4 memory T cells expressing TRAIL, terminally differentiated CD8 T cells expressing CX3CR1, and CD4 FoxP3+ regulatory T cells, cell types not expected to be involved in aGVHD pathogenesis. CD137-ADC-treated recipients demonstrated a higher risk of reactivation of rhesus lymphocryptovirus (the rhesus macaque Epstein-Barr virus analog), which was associated with reconstitution of follicular helper T cells, interferon signaling-associated memory, and γδT-cell subsets. This reactivation was controllable with rituximab administration. These results document effective depletion of alloreactive T cells and prevention of aGVHD after a single dose of CD137-ADC, suggesting that clinical translation should be carefully explored.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gerdemann U, Kimler K, Warren MR, et al. A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood. 2025. PMID: 40504994. doi:10.1182/blood.2024027239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。